New Once-Weekly Treatment for Patients With T2 Diabetes Approved by CHMP

The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for Novo Nordisk’s Awiqli a once-weekly basal insulin icodec for treatment of diabetes in adults.

The CHMP opinion is based on results from a phase 3a clinical trial program, which showed Awiqli achieved superior blood sugar reduction within the recommended range of one week, compared with daily basal insulin in people with type 2 diabetes.

Novo Nordisk expects to receive final marketing authorization from the European Commission within approximately two months.

Read the opinion here.

To read the whole story, click here to subscribe.

Related Topics